Readystate Asset Management LP Sells 77,631 Shares of Krystal Biotech, Inc. $KRYS

Readystate Asset Management LP trimmed its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 52.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 70,349 shares of the company’s stock after selling 77,631 shares during the period. Readystate Asset Management LP owned approximately 0.24% of Krystal Biotech worth $12,419,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in KRYS. Hantz Financial Services Inc. boosted its position in shares of Krystal Biotech by 8,950.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock worth $25,000 after purchasing an additional 179 shares in the last quarter. Bessemer Group Inc. raised its stake in Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after buying an additional 77 shares during the last quarter. AdvisorNet Financial Inc acquired a new stake in Krystal Biotech in the third quarter worth about $30,000. Salomon & Ludwin LLC purchased a new stake in shares of Krystal Biotech during the third quarter worth about $33,000. Finally, First Horizon Advisors Inc. increased its holdings in shares of Krystal Biotech by 212.8% during the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock valued at $34,000 after acquiring an additional 166 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Krystal Biotech

In related news, CAO Kathryn Romano sold 12,500 shares of Krystal Biotech stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $272.14, for a total value of $3,401,750.00. Following the sale, the chief accounting officer directly owned 19,318 shares in the company, valued at approximately $5,257,200.52. The trade was a 39.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the transaction, the insider directly owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. The trade was a 1.74% decrease in their position. The SEC filing for this sale provides additional information. 13.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. The Goldman Sachs Group lifted their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. TD Cowen reissued a “buy” rating on shares of Krystal Biotech in a report on Friday, January 9th. Jefferies Financial Group upped their target price on Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research report on Tuesday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday, December 29th. Finally, Citigroup increased their price objective on Krystal Biotech from $320.00 to $336.00 and gave the company a “buy” rating in a report on Monday, January 12th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $291.89.

Krystal Biotech Stock Up 4.1%

Shares of Krystal Biotech stock opened at $287.84 on Wednesday. The firm has a market cap of $8.35 billion, a PE ratio of 43.15 and a beta of 0.49. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $298.30. The business has a 50-day moving average price of $263.97 and a 200 day moving average price of $207.87.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $107.11 million for the quarter, compared to the consensus estimate of $105.30 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. On average, sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Key Krystal Biotech News

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Q4 revenue and EPS beat — VYJUVEK net product revenue of $107.1M (Q4) and $389.1M (FY), and EPS that topped estimates, supporting higher near‑term profitability. Krystal Biotech Announces Q4 and FY2025 Results
• Positive Sentiment: Regulatory designations accelerate development: FDA granted RMAT to KB707 (advanced NSCLC) and Fast Track to KB111 (Hailey‑Hailey disease), which can speed review and regulatory interactions. Quiver: 4Q Revenue & FDA Designations
• Positive Sentiment: Strong balance sheet — ~$956M in cash and investments at year‑end provides runway for multiple trials and commercialization efforts. Quiver: Cash Position
• Neutral Sentiment: Positive clinical signals in respiratory programs (KB407 cystic fibrosis cohort showed lung delivery/expression; CORAL‑3 repeat‑dose study discussions with FDA planned), supporting longer‑term upside but still early stage. GlobeNewswire: Pipeline Updates
• Negative Sentiment: The company raised FY‑2026 non‑GAAP combined R&D & SG&A guidance but did not provide a GAAP reconciliation because it cannot confidently estimate stock‑based comp — this increases uncertainty about true GAAP expense and margins. GlobeNewswire: Guidance Note
• Negative Sentiment: Rising operating costs — SG&A increased year‑over‑year (notably stock‑based comp), which could pressure operating leverage as commercialization expands. GlobeNewswire: Expense Details
• Negative Sentiment: European rollout timing risk — pricing negotiations in Germany and France could delay broader European revenue; reimbursement timelines extend into 2026–2027. Quiver: Europe Pricing Risk
• Neutral Sentiment: Investor materials and earnings call transcript provide more color on commercial cadence and trial timelines — useful for due diligence. Seeking Alpha: Earnings Call Transcript

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.